Serum beta-2-microglobulin levels in urological cancer

Area of Science:

• Oncology
• Clinical Chemistry
• Nephrology

Background:

• Serum beta-2-microglobulin (B2M) is a protein found on the surface of most cells.
• Elevated B2M levels can indicate various conditions, including certain cancers and impaired kidney function.
• The utility of B2M as a tumor marker is influenced by confounding factors like renal function.

Purpose of the Study:

• To evaluate the role of serum beta-2-microglobulin (B2M) as a potential biomarker in patients with renal, bladder (vesical), and prostate cancer.
• To assess the impact of normal renal function on B2M levels in these cancer patient cohorts.
• To determine the correlation between B2M levels and tumor stage in bladder cancer under specific renal function criteria.

Main Methods:

• Serum B2M levels were measured in patients diagnosed with renal, vesical, or prostatic cancer.
• A strict criterion of serum creatinine ≤ 105 µmol/L was applied to exclude patients with impaired renal function.
• This selection process aimed to isolate the effect of cancer on B2M levels, independent of kidney dysfunction.

Main Results:

• The renal function criterion excluded a significant proportion of patients, particularly those with bladder cancer (28–50%) and post-nephrectomy renal carcinoma (73%), limiting B2M's surveillance value in these groups.
• Serum B2M levels were rarely elevated above 3.0 mg/L in patients with prostate cancer.
• In bladder cancer patients with normal serum creatinine, elevated B2M levels showed a positive correlation with increasing tumor stage.

Conclusions:

• Serum B2M measurement is limited for surveillance in renal and post-nephrectomy bladder cancer due to high exclusion rates based on renal function.
• B2M levels are generally not significantly elevated in prostate cancer patients within the study's criteria.
• Elevated serum B2M may serve as a useful indicator for tumor progression in bladder cancer when renal function is preserved.